Webinar with Live Q&A

Generating Clinically Actionable Tissue Biomarker Data in Complex Diseases: Spotlight on Immuno-Oncology and Dermatology

Thursday, November 17, 2022

9:00 AM ET | 3:00 PM CET (Duration: 35 Minutes)

Understanding the mechanism of action or proof of concept following drug treatment may require a detailed analysis of what is happening within tissues.

Multiplex immunofluorescence is a useful approach for generating detailed information on tissues through immunophenotyping and spatial analysis pre- and post-treatment. While often applied in the immune-oncology field, this approach is also useful in autoimmune diseases and dermatology, where it is possible to source clinical biopsies more routinely.

This webinar takes a deeper dive into these complex diseases and covers important points to consider for the successful development and use of tissue-based biomarker assays.

Key points covered:

  • Approaches for tissue-based interrogation of protein biomarkers
  • Clinically actionable data - considerations for assay type and level of validation required
  • How to maximize the utility of clinical samples
  • Examples from immuno-oncology and dermatology

 

Fill out this form to register for the webinar.

About our speakers

Dr. Amanda Woodroofe - PFM

Amanda Woodrooffe, Ph.D.

Senior Vice President, General Manager UK Labs

Dr. Woodrooffe brings years of experience as a leader of scientific operations both with pharmaceutical companies and with contract research organizations, so she’s directly familiar with both sides of the table and excels as a collaborative partner. She focuses on methods and approaches to provide actionable data which can directly enable biopharmaceutical research and development.

She earned her PhD, focused on drug metabolism, from the University of Cambridge.


Dr. Darren Davis - PFM

Darren Davis, Ph.D.

Senior Vice President

Dr. Davis is a visionary leader with more than 25 years of distinguished biotechnology and clinical translational research experience. In 2004 he founded ApoCell, and was instrumental in developing and commercializing the ApoStream® rare-cell liquid biopsy technology prior to ApoCell’s acquisition by Precision for Medicine in 2018.

He earned his PhD from the University of Texas MD Anderson Cancer Center. Dr. Davis is a globally recognized cancer researcher and the author of more than 100 peer-reviewed publications.